药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Rolitetracycline
Orbifloxacin
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Orbifloxacin.
Rolitetracycline
Fenthion
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Fenthion.
Rolitetracycline
Famphur
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Famphur.
Rolitetracycline
Dichlorvos
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Dichlorvos.
Rolitetracycline
Coumaphos
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Coumaphos.
Rolitetracycline
Acrivastine
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Acrivastine.
Rolitetracycline
Flumequine
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Flumequine.
Rolitetracycline
Chlorcyclizine
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Chlorcyclizine.
Rolitetracycline
Eribulin
The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dabrafenib.
Rolitetracycline
Bupranolol
The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Dabrafenib.
Rolitetracycline
Geranylgeranyl diphosphate
The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Dabrafenib.
Rolitetracycline
Farnesyl diphosphate
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Dabrafenib.
Rolitetracycline
Triptorelin
The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dabrafenib.
Rolitetracycline
Histrelin
The risk or severity of QTc prolongation can be increased when Histrelin is combined with Dabrafenib.
Rolitetracycline
Buserelin
The risk or severity of QTc prolongation can be increased when Buserelin is combined with Dabrafenib.
Rolitetracycline
Degarelix
The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dabrafenib.
Rolitetracycline
Cariporide
The risk or severity of QTc prolongation can be increased when Cariporide is combined with Dabrafenib.
Rolitetracycline
Amisulpride
The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Dabrafenib.
Rolitetracycline
Vernakalant
The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Dabrafenib.
Rolitetracycline
Tandutinib
The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Dabrafenib.